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Review Article
INTRODUCTION
Epstein-Barr virus (EBV)-positive mucocutaneous ulcers 
(EBVMCUs) were first described as a distinct clinicopatho-
logical entity in 2010 when Dojcinov et al. reported 26 
patients with ulcerative lesions confined to the oropharynx, 
skin, and gastrointestinal tract.1   The lesions were character-
ized by the proliferation of EBV-positive, variably sized, 
atypical B-cells that may resemble Hodgkin and Reed-
Sternberg (HRS)-like cells.   As the patients were immuno-
suppressed, demonstrating either age-related immunosenes-
cence or iatrogenic immunosuppression, EBVMCUs were 
later described as a new disease type by the World Health 
Organization.2
EBVMCUs are shallow, sharply circumscribed, mucosal 
or cutaneous ulcers with underlying polymorphous infiltra-
tion.   The HRS-like cells that are observed in the lesions, as 
well as any observed immunoblasts, demonstrate B-cell 
immunophenotypes, i.e., CD20 expression; therefore, the 
ulcers were originally classified as EBV-positive diffuse large 
B-cell lymphomas (EBV-positive DLBCLs), but were later 
recognized as a unique disease type, pathologically distinct 
from lymphomas.   However, some characteristics of 
EBVMCUs overlap with those of immunodeficiency-associ-
ated lymphoproliferative disorders (LPDs).
In general, patients with EBVMCUs exhibit indolent dis-
ease progression and spontaneous regression.   Although 
radiotherapy or chemotherapy may be considered as thera-
peutic options, most patients have spontaneous regression 
when their immunosuppression is reduced or discontinued; 
only one disease-associated death has been reported.3   In this 
article, we describe the clinicopathological aspects of 
EBVMCUs.
EBV BIOLOGY
EBV, also known as human herpes virus 4, is a member 
of the herpes virus family and is one of the most common 
human viruses.4-8   Approximately 95% of people become 
infected with this virus during childhood because it may be 
directly transferred between individuals through saliva. 
Although infections sometimes manifest as infectious mono-
nucleosis, many are asymptomatic.
EBV preferentially infects B lymphocytes through the 
interaction of the major viral surface glycoprotein (gp350) 
with a B lymphocyte receptor (CD21); a second viral 
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glycoprotein (gp42) also binds the class II major histocom-
patibility complex molecules on the B lymphocyte, which 
function as co-receptors for the virus.   In most people, EBV 
infections are transient, but some malignant tumors are asso-
ciated with EBV infections (Table 1).   EBV is also associ-
ated with malignant lymphomas and LPDs, including 
DLBCL, classic Hodgkin lymphoma (cHL), Burkitt lym-
phoma (BL), immunodeficiency-associated LPDs, and extra-
nodal NK/T cell lymphoma, nasal type.
By minimizing viral gene transcription, EBVs can avoid 
the host immune response; however, the mechanism by 
which the virus is able to avoid the host immune response 
has not been elucidated.   The EBV infection process has two 
phases, a lytic and a latent phase.   First, during the lytic 
phase, the virus particles are amplified.   Then, during the 
latent phase, the viral genome is maintained within the host 
cell.   During the latent phase, viral gene products upregulate 
the expression of a variety of B-cell genes.   EBV-infected 
cells express only six types of nuclear proteins (EBNA1, 2, 
3A-C, and LP) and three types of membrane proteins (LMP1, 
LMP2A, and LMP2B), which mediate the transforming role 
of EBV in B cells.   The latency phase of the infection may 
be described as one of three types, each determined by the 
specific viral gene expression pattern.   In Latency I, EBV 
expresses only EBNA1, which is expressed in all infected 
cells, and causes viral genome maintenance and replication. 
Latency II is an intermediate pattern involving the expression 
of many proteins.   Latency IIa is a transitional form of 
Latency III that helps the infected cells avoid cytotoxic T 
lymphocytes.   This form is characterized by the expression 
of LMP1, LMP2A, and EBNA1, and the expression of EBV-
encoded small RNAs and BamHI fragment A rightward tran-
script microRNA.   Latency IIb is a form that precedes the 
transition to Latency III and is characterized by the expres-
sion of EBNA2 without LMP1 expression.9   Latency III is a 
phase during which all gene products are expressed. 
Latency I is associated with BL, Latency II is associated with 
cHL and NK/T cell lymphoma, and Latency III is associated 
with immunodeficiency-associated LPDs.
During EBV infection, the molecular pathways that con-
trol the cell cycle and suppress apoptosis are activated; 
LMP1 is one of the important factors involved in activating 
these pathways.   LMP1 activates the nuclear factor-κB (NF-
κB) pathway, and NF-κB transcription factors control lym-
phoid cell proliferation and hyperactive NF-κB signaling pro-
motes malignant transformation.   EBV-infected cells also 
express the bcl-2 protein, which may enable the cells to 
become resistant to apoptosis.
EBV-ASSOCIATED LPDs
Among the EBV-associated LPDs, immunodeficiency-
associated LPDs have been garnering attention in recent 
years.10-12   Immunosuppression is believed to affect the 
homeostasis of the persistent infection state, enabling the 
appearance of EBV-associated LPDs.   In the World Health 
Organization disease classification, there are four categories 
of immunodeficiency-associated LPDs: LPDs associated with 
primary immune disorders, lymphomas associated with 
human immunodeficiency virus (HIV) infections, post-trans-
plant LPDs (PTLDs), and other iatrogenic immunodefi-
ciency-associated LPDs (Oii-LPDs).   Some Oii-LPD cases 
fulfill the pathological concept of DLBCLs, NK/T cell lym-
phomas, and cHL.   For example, Oii-LPDs sometimes 
exhibits HRS cells that are positive for CD30.   In Asia, 
including in Japan and Korea, there are many reports of Oii-
LPDs following methotrexate (MTX) treatment.   Oyama et 
al. reported EBV-positive DLBCLs in elderly (>60 years old) 
Japanese patients without predisposing immunodeficiencies.11 
They suggested that EBV-positive DLBCLs are related to the 
immune depression resulting from the aging process.   Thus, 
in 2010, ulcerative lesions related to iatrogenic immunosup-
pression or age-related immunological deterioration were 
recognized as EBVMCUs.1,13
EBVMCU CLINICAL FEATURES
Among EBVMCU case reports to date, the median patient 
age was 66.4 years (range, 16-101 years, Table 21,3,6,14-48), 
with a slight female predominance; female patients com-
prised 58.3% of cases.   Factors contributing to the female 
prevalence may include some that are involved in rheumatoid 
arthritis, which is also more common among females than 
males.   Patients demonstrate sharply circumscribed mucosal 
B-cell lymphoproliferations
   Infectious mononucleosis
   EBV-positive diffuse large B-cell lymphoma, NOS
   EBV-positive mucocutaneous ulcer
   Diffuse large B-cell lymphoma associated with chronic inflammation
   Lymphomatoid granulomatous
   Plasmablastic lymphoma
   Burkitt lymphoma
   Classical Hodgkin lymphoma
   Immunodeficiency-associated lymphoproliferative disorders
      LPD associated with primary immune deficiencies
      Lymphomas associated with HIV
      Post-transplant lymphoproliferative disorders
      Other iatrogenic immunodeficiency-associated lymphoproliferative 
disorders
T-cell lymphoproliferations
   EBV-positive T-cell and NK cell lymphoproliferative diseases of 
childhood
   Aggressive NK-cell leukemia
   Extranodal NK/T-cell lymphoma, nasal type
   Primary EBV-positive nodal T- or NK-cell lymphoma
Epithelial cell malignant tumors
   Nonglandular nasopharyngeal carcinoma
   Lymphoepithelioma-like carcinoma (salivary, thymus, lungs, stomach)
   Breast carcinoma
   Hepatocellular carcinoma
Mesenchymal malignant tumors
   Leiomyosarcoma
   Follicular dendritic cell sarcoma
Table 1. EBV-associated diseases.
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or cutaneous ulcers,49 with >70% of the ulcers occurring in 
the oral mucosa (Figure 1).   As EBVs are secreted into saliva 
and local trauma or inflammation is likely to occur in the oral 
cavity, there is a possibility of EBVMCUs developing intra-
orally.50   Some cases result in eating disorders without any 
systemic symptoms, including lymph node swelling or B 
symptoms, i.e., fever, night sweats, and weight loss.
EBVMCUs emerge when the host-virus homeostasis is 
not maintained, i.e., when the virus overwhelms the host’s 
immune response.   Specifically, ulcer eruption may result 
from immune abnormalities caused by inflammation and 
immunosuppression.   Dojcinov et al. first reported the ulcers 
in patients characterized by advanced age who were undergo-
ing iatrogenic immunosuppression using MTX, azathioprine, 
cyclophosphamide, or tumor necrosis factor-α inhibitor.1 
Patients with EBVMCUs who were not using immunosup-
pressants were elderly (>60 years old), leading to the sugges-
tion that EBVMCUs also develop as a result of age-associ-
ated immunodeficiency that is mainly caused by T cell 
hypofunction.1   After their report, EBVMCUs were also 
reported in patients with primary immunodeficiencies,14,15 
solid organ or bone marrow transplant recipients,16-19 and in 
those with HIV/ acquired immune deficiency syndrome 
(AIDS).20   One case of ulceration was reported in an immu-
nosuppressed patient with inflammatory bowel disease; there-
fore, the possibility of EBVMCUs being involved in such 
cases needs to be considered.21   Among the previously 
reported cases, 80 (66.1%) were iatrogenic immunodefi-
ciency-associated EBVMCUs and 33 (27.3%) were associated 
with age-associated immunosenescence.   EBVMCUs have 
also been reported in patients with primary immunodeficien-
cies (3 cases) and in those with HIV/AIDS (2 cases).   During 
follow-up (1-180 months), spontaneous regression was 
observed in 6 cases and complete remission was observed in 
79 cases following the reduction of immunosuppression, che-
motherapy, or radiotherapy; 7 cases relapsed,1,3,38 but only 3 
developed progressive disease.3,15,22
Before EBVMCUs were defined, there were several 
Cases Mean age(years)
Age range
(years)
Sex
(male/female)
Other Iatrogenic Immunodeficiency-Associated EBVMCU
      Oropharyngeal
      Skin
      Gastrointestinal
46
14
20
65.2
66.2
59.9
17-84
49-81
26-81
17/ 29
3/ 11
11/ 9
EBVMCU due to age-associated immunosenescence
      Oropharyngeal
      Skin
      Gastrointestinal
23
7
3
76.7
81.3
69.3
51-101
74-89
64-79
10/13
5/2
1/ 2
HIV/AIDS-Associated EBVMCU
      Palate 2 cases (54-year-old male, 36-year-old female)20
Primary Immunodeficiency-Associated EBVMCU
      Gingiva
      Esophagus
      Nasopharyngeal
45-year-old female with T-cell deficiency14
61-year-old male with hypogammaglobunemia15
16-year-old male with CHARGE syndrome3
Chronic Antigenic Stimulation-Associated EBVMCU
      Sinus 59-year-old female46
EBVMCU of Unclear Etiology
      Oropharyngeal 2 cases (49-year-old female, 49-year-old female)3, 6
Total 121 66.4 16-101 50/71
Table 2. Case reports and series. (2010-2018)
EBVMCU cases in 2010 to 2018.1, 3, 6, 14-48
Fig. 1. 
Macroscopic findings of a gingival Epstein-Barr virus-positive 
mucocutaneous ulcer.
The ulcer appearance  while the patient was undergoing methotrex-
ate treatment (A). After reducing the methotrexate dose, the lesion 
spontaneously resolved (B).
A B
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reports of oral ulcerations occurring as a side effect of MTX 
therapy.51   In such cases, the ulcers regressed following 
reductions in the immunosuppression regimes.   Thus, these 
ulcers were not considered to be EBV-related, but rather the 
result of treatment-associated toxicity.   These ulcers were 
also regarded as being nonspecific based on microscopic 
observations; however, most of the case reports only 
described the associated clinical features without histological 
evaluation.
CLINICAL MANAGEMENT AND PROGNOSIS
Almost all EBVMCU cases have some degree of sponta-
neous regression following cessation or reduction of the 
immunosuppressive treatment for autoimmune disorders such 
as rheumatoid arthritis.   Some patients with these lesions 
have been treated by radiotherapy and rituximab or other 
forms of chemotherapy, and often demonstrate complete 
remission.   However, whether the lesions responded to the 
treatment or spontaneously resolved remains unknown.
The ulcers rarely spread to distant sites, but they have 
been observed to spread locally and relapse after regression. 
Hodgkin lymphoma (HL)-like EBVMCUs sometimes do not 
regress.52   Therefore, the patients in such cases are treated by 
radio- or chemotherapy; these patients also often exhibit 
remission.   As progressive disease and the subsequent devel-
opment of HL was observed in a rare case, the ulcers may 
also be associated with HL.22   Other than this one case, there 
has been only one disease-associated death among the 
reported cases and series.3   Thus, other EBV-positive LPDs 
have a poorer prognosis than EBVMCUs.
PATHOLOGICAL FEATURES
The localized mucosal or cutaneous ulcers are character-
ized by the presence of EBV-positive atypical immunoblasts 
or HRS-like cells (Figure 5).   The atypical cells range in size 
from small to large, and accompany dense polymorphic infil-
tration with the variable presence of other inflammatory cells 
such as plasma cells (polymorphous type) (Figure 2, 4). 
Some cases have demonstrated histological findings similar 
to those associated with DLBCL or cHL (Figure 3, 5). 
Occasionally atypical lymphoid cells demonstrated plasma-
cytoid features (Figure 6).   In these cases, the cells exhibit 
characteristics of activated B lymphocytes, including (in 
most cases) CD20 and CD30 expression.   These cells are 
often also positive for CD79a, PAX5, and OCT2, with vari-
able expression of BOB1.   CD15 is expressed in approxi-
mately half of the cases and MUM1 is typically expressed.2 
These immunohistochemical results strongly support the 
origination of these atypical cells from B cells.   Although 
these histological findings are similar to those associated with 
cHL, many of the B lymphocytes being CD20-positive is dif-
ferent from cHL.   In addition, extranodal lesions are rare in 
patients with cHL.   Thus, cHL and EBVMCU can be distin-
guished based on their respective clinicopathological fea-
tures.   HRS-like cells are seen in EBV-positive LPDs, but 
Fig. 2. 
A cutaneous Epstein-Barr virus-positive mucocutaneous ulcer (poly-
morphous type) on the lower leg of a 72-year-old female undergoing 
methotrexate treatment.
Atypical lymphoid cells with a polymorphous morphology are infil-
trating the epidermal, dermal, and subcutaneous tissues.
After reducing the methotrexate dose, the lesion spontaneously 
resolved.
Fig. 3. 
An Epstein-Barr virus-positive mucocutaneous ulcer (diffuse large 
B-cell lymphoma [DLBCL] type) in the nasopharyngeal mucosa of 
an 80-year-old female undergoing methotrexate treatment.
This case resembles DLBCL morphology.
The lymphoid cells are positive for CD20 and Epstein-Barr virus-
encoded small RNA.
Following chemotherapy that included rituximab, the lesion showed 
complete remission.
CD20 EBER
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the B lymphocytes in patients with infectious mononucleosis 
or PTLD are CD30-positive and CD15-negative; CD15 
expression is also downregulated in cases of EBV-positive, 
MTX-associated LPD.
Mucosal and cutaneous EBVMCU lesions exhibit dense 
polymorphic infiltration with the variable presence of inflam-
matory cells, including plasma cells, histiocytes, lympho-
cytes, and eosinophils.   Apoptotic bodies and necrosis are 
also often noted.   These infiltrating lymphocytes are mainly 
CD8-positive T cells and 31% of them demonstrate T cell 
receptor (TCR) gene rearrangements.1
EBV-positive DLBCL is a disease that requires distinc-
tion from EBVMCUs based on its histology and prognosis. 
EBV-positive DLBCLs were initially reported to be associ-
ated with aging.   This disease is characterized by poor out-
comes, and is a high-grade lymphoma that presents with 
CD20-positive, CD30-positive, and sometimes CD15-
positive HRS-like cells.   Polymerase chain reaction charac-
terization revealed more clonal immunoglobulin heavy chain 
(IgH) gene rearrangements associated with EBV-positive 
DLBCL than with EBVMCUs.1,13   However, differentiating 
between EBVMCUs and EBV-positive DLBCLs is difficult. 
Aside from EBVMCUs typically being “localized lesions”, 
consideration of the clinical findings is necessary when dis-
tinguishing between the two.
GENETIC FEATURES
There are several reports on the search for clonality in 
age-related and immunodeficiency-related EBVMCUs.1,23 
Dojcinov et al. reported that 38% of their cases exhibited IgH 
gene rearrangements and 31% exhibited TCR gene rearrange-
ments when evaluated using polymerase chain reaction. 
Fig. 4. 
A gingival Epstein-Barr virus-positive mucocutaneous ulcer (poly-
morphous type) in a 91-year-old male undergoing methotrexate 
treatment.
The lesion showed polymorphous morphology with Hodgkin and 
Reed-Sternberg-like cells.
Fig. 5. 
A gingival Epstein-Barr virus-positive mucocutaneous ulcer (diffuse 
large B-cell lymphoma [DLBCL] type) in a 69-year-old male.
Large, atypical lymphoid cells, with plasmacytoid differentiation are 
infiltrating the subepithelial lesion.
This lesion is similar to a DLBCL with plasma cell differentiation.
These atypical lymphoid cells are CD20-negative and positive for 
CD79a and Epstein-Barr virus-encoded small RNA.
Immunoglobulin light chain analysis, using in situ hybridization, 
showed a κ chain monotype.
Fig. 6. 
A lingual Epstein-Barr virus-positive mucocutaneous ulcer 
(mucosa-associated lymphoid tissue lymphoma type) in a 66-year-
old female undergoing methotrexate treatment.
Atypical, medium-sized lymphoid cells demonstrate plasmacytoid 
features and Russel bodies.
In situ hybridization shows that the atypical cells are Epstein-Barr 
virus-encoded small RNA-positive.
After reducing the methotrexate dose, the lesion spontaneously 
regressed.
CD79a EBER
Igκ(ISH) Igλ(ISH)
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Age-related EBVMCUs have been found to have lower clon-
ali ty than EBV-posit ive DLBCLs,13 suggesting that 
EBVMCUs are not true tumors.
As EBV-positive cells are B lymphocytes, the IgH gene 
rearrangements of EBVMCUs are associated with B cells. 
Furthermore, EBVMCUs may present TCR gene rearrange-
ments even though EBV-positive cells are B cells.   A previ-
ous report suggested that TCR gene rearrangements are asso-
ciated with a limited T cell repertoire associated with EBV 
infections in patients who are aged and immunosuppressed.1 
The T cells responsible for immune responses are the mature 
memory T cells that are CD8-positive.   It is possible that T 
cells cannot recognize the EBV epitope because T cell epit-
ope recognition is restricted in older patients and in those 
with other immunodeficiencies.53   This may enable an 
increase in the number of EBV-positive cells.   As a result, 
the human body may allow the proliferation of mature mem-
ory T cells to elicit an immune response and be involved in 
clonality.
Ohata et al. investigated several gene mutations (MYD88, 
CD79A, CD79B, CARD11, and EZH2), and although none 
were associated with EBVMCUs, more than 30% of tumor 
tissues from EBV-negative DLBCLs contained mutations.24
CONCLUSION
EBVMCUs are a newly described entity in the World 
Health Organization classification.2   They are ulcerative 
lesions localized to the skin and mucosa that are character-
ized by the presence EBV-positive variably sized B-cells. 
To appropriately treat EBVMCUs, clinicians need to be able 
to distinguish them from DLBCLs and cHL based on their 
clinicopathological findings.   Although there is currently no 
established treatment regimen due to the lack of evidence, 
future case studies are expected to rectify this.
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